In-Licensing a Drug Candidate for Obstructive Sleep Apnea from Bayer
First written in FY2025. 2 of 4 entries say "Advanced", first in FY2026-H1. Latest entry: 2026-07-30.
No other company in this theme has enough history to compare yet.
- 2026-07-30AdvancedEarnings presentation
「KRP-S124 Obstructive sleep apnea, etc. Phase 1 (completed) Phase 2 scheduled to start in FY2026」
KRP-S124 progressed from the preparation stage to completion of the Phase 1 trial and a scheduled Phase 2 start in FY2026. The original thread remains unchanged. - FY2026RestatedAnnual report
「For KRP-S124, a drug for obstructive sleep apnea in-licensed from Bayer (headquartered in Germany) in December 2024, the Company is preparing to conduct a Phase 2 clinical trial.」
The Company continues to prepare for a Phase II clinical trial of KRP-S124. - FY2026-H1AdvancedAnnual report
「For KRP-S124, a drug for obstructive sleep apnea in-licensed from Bayer in December 2024, the Company is preparing for a Phase 2 clinical trial.」
KRP-S124, which was in-licensed from Bayer, progressed to the preparation stage for a Phase 2 clinical trial. - FY2025First statedAnnual report
「In December 2024, we entered into a license agreement with Bayer for a novel drug candidate for obstructive sleep apnea and a backup compound, acquiring exclusive worldwide rights to manufacture, develop and market them.」
Exclusive worldwide manufacturing, development and marketing rights were acquired from Bayer for novel drug candidates for obstructive sleep apnea.